We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Observers on all sides of the dispute over Medicare coverage of certain compounded drugs are anxiously awaiting the Centers for Medicare & Medicaid Services' (CMS) decision about what factors will be considered in setting reimbursement rates.
Sen. Chuck Grassley (R-Iowa) sent a letter to HHS Secretary Mike Leavitt requesting that he convene a meeting of the Secretary’s Advisory Committee on Human Research Protections (SACHRP) to address a controversial study of a blood substitute that is being done under an emergency exception rule.
The government’s effort to compare different drug products is moving forward, with the NIH’s National Eye Institute funding a clinical trial comparing two drugs used to treat advanced age-related macular degeneration (AMD), the leading cause of blindness among the elderly.
On the same day that the FDA held a public hearing on clinical research conducted under an emergency exception rule, Sen. Chuck Grassley (R.-Iowa) sent a letter to HHS Secretary Mike Leavitt requesting that he convene a meeting of the Secretary’s Advisory Committee on Human Research Protections (SACHRP) to address a controversial study of a blood substitute that is being done under that rule.
The government’s effort to compare different drug products is moving forward, with the NIH’s National Eye Institute funding a clinical trial comparing two drugs used to treat advanced age-related macular degeneration (AMD), the leading cause of blindness among the elderly.
Several controversial healthcare issues are beginning to make headway in Congress, with drug importation, biodefense and National Institutes of Health (NIH) legislation taking important steps toward becoming law last week.
Several controversial healthcare issues are beginning to make headway in Congress, with drug importation, biodefense and National Institutes of Health (NIH) legislation taking important steps toward becoming law in the past week.
FDA officials said they welcomed the Institute of Medicine (IOM) report “The Future of Drug Safety: Promoting and Protecting the Health of the Public,” but reserved reacting to most of the recommendations until they have had time to review the report.
The FDA should be given the authority to impose severe punishments on drug manufacturers who don’t live up to their postmarketing commitments, according to an Institute of Medicine (IOM) report that offered a harsh assessment of the agency’s current drug safety efforts.
Seniors could enjoy several more weeks or even months of drug cost coverage under Medicare by using generic instead of brand drugs, according to a new report by the Pharmaceutical Benefit Care Association (PCMA).